Robeco Institutional Asset Management B.V. Raises Holdings in Illumina, Inc. (NASDAQ:ILMN)

Robeco Institutional Asset Management B.V. increased its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 74.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 276,506 shares of the life sciences company's stock after acquiring an additional 117,730 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.17% of Illumina worth $36,059,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ILMN. Vanguard Group Inc. lifted its position in shares of Illumina by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company's stock worth $2,505,409,000 after purchasing an additional 66,528 shares during the period. Bank of New York Mellon Corp boosted its position in Illumina by 7.2% during the second quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company's stock valued at $317,267,000 after acquiring an additional 204,043 shares during the last quarter. Capital World Investors grew its holdings in Illumina by 41.1% during the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company's stock worth $378,111,000 after acquiring an additional 801,814 shares during the period. Primecap Management Co. CA raised its position in shares of Illumina by 462.5% in the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company's stock worth $253,514,000 after acquiring an additional 1,997,010 shares in the last quarter. Finally, GUARDCAP ASSET MANAGEMENT Ltd lifted its stake in shares of Illumina by 1.1% in the 1st quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 2,068,869 shares of the life sciences company's stock valued at $284,097,000 after purchasing an additional 22,067 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Down 2.0 %

Shares of NASDAQ ILMN traded down $3.13 during midday trading on Wednesday, reaching $151.83. The company's stock had a trading volume of 2,815,785 shares, compared to its average volume of 1,731,745. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a 50 day moving average price of $137.27 and a 200-day moving average price of $123.12. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 6.36% and a negative net margin of 36.10%. The business's revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.33 EPS. As a group, analysts anticipate that Illumina, Inc. will post 3.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. raised their target price on Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a research note on Tuesday. Royal Bank of Canada raised their price objective on shares of Illumina from $252.00 to $254.00 and gave the stock an "outperform" rating in a research report on Tuesday. Stephens reiterated an "overweight" rating and set a $170.00 target price on shares of Illumina in a research report on Wednesday, July 10th. Piper Sandler reduced their price target on shares of Illumina from $200.00 to $195.00 and set an "overweight" rating for the company in a report on Tuesday, August 13th. Finally, Hsbc Global Res upgraded shares of Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Illumina currently has an average rating of "Moderate Buy" and an average target price of $162.18.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.